New hepatitis c drug shows early promise in small study
NCT ID NCT00591214
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus levels. This is a first step to see if the drug might help control the infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MP-424 (telaprevir)
- What this could lead to
- If this drug proves safe and effective, it could become part of a treatment to control hepatitis C virus levels.
- What could go wrong
- This is a very early, small Phase 1 trial with only 10 participants. It focuses on safety and drug levels, not cure. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Massive study aims to map hepatitis c elimination in pakistan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New hepatitis c drug combo shows promise in early trial
- New study tests faster hepatitis c detection for drug users
- New hope: hepatitis c drugs after liver cancer treatment